Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and its Mutated Variants: Challenges and Future Directions

ABSTRACT

The aim of this study is to investigate the efficacy of interleukin-6 (IL-6) inhibitor antibodies as a therapeutic agent to combat severe COVID-19. Given the constant evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the study aims to assess the potential of these inhibitors in adapting to new challenges and improving treatment outcomes. A comprehensive review of relevant literature was conducted using electronic databases such as Web of Science, PubMed, EMBASE, Scopus, and Google Scholar. The study analyzed the role of IL-6 inhibitors in combating SARS-CoV-2, focusing on their therapeutic potential in treating severe COVID-19 cases, particularly in controlling the overshooting immune response associated with cytokine storms. IL-6 inhibitors proved to be versatile and effective in attenuating severe immune responses, especially cytokine storms, which are common in advanced COVID-19 cases. The literature emphasizes their ability to regulate the immune system, reduce disease severity, and improve patient outcomes. Their efficacy in controlling the immune response and reducing disease severity makes IL-6 inhibitor antibodies a promising therapeutic strategy for severe SARS-CoV-2 and its new variants. Further research is needed to optimize their use and adaptability in evolving clinical scenarios.

KEYWORDS

• Severe acute respiratory syndrome coronavirus 2
• cytokine storm
• interleukin-6 inhibitors
• tocilizumab
• sarilumab

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/0976500X251316939Copy